MENU
+Compare
VKTX
Stock ticker: NASDAQ
AS OF
Nov 20, 04:59 PM (EDT)
Price
$34.26
Change
-$1.78 (-4.94%)
Capitalization
3.87B

VKTX Viking Therapeutics Forecast, Technical & Fundamental Analysis

Viking Therapeutics Inc is a healthcare service provider... Show more

Industry: #Biotechnology
VKTX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for VKTX with price predictions
Nov 19, 2025

Momentum Indicator for VKTX turns negative, indicating new downward trend

VKTX saw its Momentum Indicator move below the 0 level on November 19, 2025. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 89 similar instances where the indicator turned negative. In of the 89 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for VKTX moved out of overbought territory on November 13, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 39 similar instances where the indicator moved out of overbought territory. In of the 39 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 50 cases where VKTX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for VKTX turned negative on November 17, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where VKTX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

VKTX broke above its upper Bollinger Band on November 11, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The 50-day moving average for VKTX moved above the 200-day moving average on October 31, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where VKTX advanced for three days, in of 282 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 191 cases where VKTX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.432) is normal, around the industry mean (27.606). P/E Ratio (0.000) is within average values for comparable stocks, (52.154). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.053). Dividend Yield (0.000) settles around the average of (0.047) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (329.190).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. VKTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VKTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
VKTX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

VKTX is expected to report earnings to rise 9.88% to -88 cents per share on February 11

Viking Therapeutics VKTX Stock Earnings Reports
Q4'25
Est.
$-0.89
Q3'25
Missed
by $0.11
Q2'25
Missed
by $0.13
Q1'25
Missed
by $0.08
Q4'24
Missed
by $0.04
The last earnings report on October 22 showed earnings per share of -81 cents, missing the estimate of -69 cents. With 3.68M shares outstanding, the current market capitalization sits at 3.87B.
A.I. Advisor
published General Information

General Information

a company that engages in the development of therapies for metabolic and endocrine disorders

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
9920 Pacific Heights Boulevard
Phone
+1 858 704-4660
Employees
27
Web
https://www.vikingtherapeutics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TAGDX15.49N/A
N/A
Transamerica Large Growth R6
MFECX131.97N/A
N/A
MFS Growth C
SGRAX27.46N/A
N/A
Allspring Growth A
SAMVX12.73N/A
N/A
Virtus Ceredex Mid-Cap Value Equity A
AZBIX24.48-0.06
-0.24%
Virtus Small-Cap Institutional

VKTX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, VKTX has been loosely correlated with SYRE. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if VKTX jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VKTX
1D Price
Change %
VKTX100%
-4.56%
SYRE - VKTX
45%
Loosely correlated
+0.83%
NEVPF - VKTX
45%
Loosely correlated
N/A
GPCR - VKTX
44%
Loosely correlated
+5.57%
IMTX - VKTX
42%
Loosely correlated
N/A
RGNX - VKTX
41%
Loosely correlated
-2.84%
More